Free Trial
LON:YGEN

Yourgene Health (YGEN) Share Price, News & Analysis

Yourgene Health logo

About Yourgene Health Stock (LON:YGEN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
0.52
0.52
52-Week Range
N/A
Volume
13.15 million shs
Average Volume
21.98 million shs
Market Capitalization
£16.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. It develops in vitro diagnostic products, such as IONA Test, a non-invasive pre-natal test (NIPT) for Down's syndrome, Edwards' syndrome, and Patau's Syndrome in pregnant women; Cystic Fibrosis Screening tests; Rapid Aneuploidy Analysis, a confirmatory diagnostic test carried out after amniocentesi; and Recurrent Pregnancy Loss, a PCR assay for the routine diagnosis of the six most common chromosomes related to pregnancy loss, as well as DPYD genotyping products. The company also offers Ranger, a technology platform for sample size selection and enrichment; Elucigene DPYD assay, a PCR test to predict a patient's response to a chemotherapy treatment; and Clarigene SARS-CoV-2 CE-IVD, a PCR assay used for routine COVID-19 testing. In addition, it provides genomic services; sample preparation and analysis tools; and bioinformatics and software products, as well as extraction for DNA, RNA/miRNA, and nucleons; quantification; genotyping; gene expression; methylation; and microarray services for clinical research organizations. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. Yourgene Health Plc was incorporated in 2000 and is headquartered in Manchester, the United Kingdom. As of September 8, 2023, Yourgene Health Plc operates as a subsidiary of Novacyt UK Holdings Limited.

Receive YGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yourgene Health and its competitors with MarketBeat's FREE daily newsletter.

YGEN Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
See More Headlines

YGEN Stock Analysis - Frequently Asked Questions

Shares of YGEN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Yourgene Health investors own include HSBC (HSBA), Imperial Brands (IMB), Antofagasta (ANTO), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Barclays (BARC) and B&M European Value Retail (BME).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
LON:YGEN
CIK
N/A
Fax
N/A
Employees
253
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
9
Net Income
-£8.17 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£29.67 million
Price / Cash Flow
1.53
Book Value
GBX 4 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
3,190,000,000
Free Float
N/A
Market Cap
£16.43 million
Optionable
Not Optionable
Beta
0.86
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (LON:YGEN) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners